Navigation Links
Breast in Biological Technology

The Breast Cancer Therapeutics Market in Australia

SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cance...

Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy. QI is...

Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer

RARITAN, N.J., July 13 /PRNewswire/ -- Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncol...

New MRI technique could mean fewer breast biopsies in high-risk women

MADISON A University of Wisconsin-Madison biomedical engineer and colleagues have developed a method that, applied in MRI scans of the breast, could spare some women with increased breast cancer risk the pain and stress of having to endure a biopsy of a questionable lump or lesion. The univers...

Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer

- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported that the St. Galle...

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally ad...

DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research

DNA Genotek to Provide Method for Easy, Reliable and Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure® Ottawa, ON (PRWEB) June 12, 2009 -- DNA Genotek , a leading provider of products for biological sample collection, today announced ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple s...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting

BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR 100th Annual Meeting 2009 in Denver. "This research represents a significan...

Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial

- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall - TUSTIN, Ca...

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc. , (Nasdaq: CLRT ), a premier anatomic pathology and mol...

Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(T...

Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gall...

Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging

MOUNTAIN VIEW, Calif., Feb. 19 /PRNewswire/ -- Based on its recent analysis of the medical imaging market, Frost & Sullivan presents Naviscan, Inc. with the 2009 North American Frost & Sullivan Award for Emerging Technology of the Year. The Award recognizes the company's impressive progre...

New Study Reports Improved Patient Outcomes for Breast Cancer Patients

VALENCIA, Calif., Feb. 18 /PRNewswire/ -- A new clinical study published this month in The Breast Journal (Vol. 15, No. 1) reports that high-quality patient outcomes for breast-conserving surgery can be achieved in the community hospital setting. This is one of the few and the most recent studie...

Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, MammaPrint(R), has been published in Breast Cancer Re...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, today announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the Janua...

Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL

HUNTINGTON BEACH, California and AMSTERDAM, February 4 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer test MammaPrint(R) will be offered as standard of care for all eligible early stage breast cancer patients at the Net...

BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative

INDIANAPOLIS, Jan. 6 /PRNewswire/ -- The Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Indianapolis has partnered with BioStorage Technologies, Inc. (BST) for secure, compliant storage of donated tissue specimens. BST will store a third of the tissue bank's existi...

Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium

EMERYVILLE, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) will present findings on the mechanism of action of its anti-cancer agent BN107 at the 31st Annual San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center, San Antonio TX, Decemb...

Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA

CHICAGO, Dec. 5 /PRNewswire/ -- Early clinical experience with the FDA cleared Visica 2(TM) Treatment System from Sanarus Medical confirms the effectiveness of ultrasound guided cryoablation to completely eradicate small, unifocal Invasive Ductal Breast Cancer (IDC). Initial data from this multi-...

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Cente...

New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema

NEWPORT NEWS, Va., and SAN DIEGO, Dec. 2 /PRNewswire/ -- The Patient Advocate Foundation (PAF), with support from ImpediMed Ltd. (ASX: IPD), is pleased to announce the launch of the Lymphedema CareLine (LCL). PAF, through its MedCare Division, is offering the national, toll-free patient/provider h...

China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe

- the First SFDA Approved FISH Probe in China BEIJING, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic pro...

Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated

- Seventh Study Showing Oncotype DX Frequently Changes Treatment Recommendations in Clinical Practice - REDWOOD CITY, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced the publication of results from a study indicating that Onco...

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

SAN MARINO, Calif., Oct. 29 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designe...

Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests

OSLO, October 28 /PRNewswire-FirstCall/ -- DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services With this laboratory service and following CE marking sched...

James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30

Xceed Molecular will feature Ziplex automated gene-expression system at the conference, booth 519 WELLESLEY, Mass., Oct. 28 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that renown...

Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain'

SAN FRANCISCO, Oct. 24 /PRNewswire/ -- Researchers at 28th annual National Academy of Neuropsychology (NAN) Conference in New York City this weekend will present data to help physicians understand more about cognitive remediation training in breast cancer survivors affected by "Chemobrain". Ch...

Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress

BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that advanced breast cancer detection through the use of mammary ductoscopy was a featured topic and reviewed in panel discussions at the 94th Annual American College of Surgeons Clinical...

Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

-Data Update Shows 71% of Evaluable Patients in the Trial's First Stage Achieved Objective Tumor Responses- -Patient Enrollment is Open in the Trial's Second Stage- TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cli...

Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery

Surprisingly, a high percentage of women aren't aware of the advanced products that can help restore a positive body image ATLANTA, Oct. 16 /PRNewswire/ -- Women have more options than ever before when facing breast cancer. With early diagnosis, great strides have been made in treatm...

23andMe Announces Breast Cancer Initiative

Personal Genetics Leader to Focus on Building DNA-based Community For Women Impacted by Breast Cancer CARLSBAD, Calif., Oct. 2 /PRNewswire/ -- 23andMe, Inc., the industry leader in personal genetics, today announced that it is embarking on a world-wide effort to assemble the largest cohort o...

Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast ...

alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both

Research Indicates Being Overweight Increases Risk of Breast Cancer PARSIPPANY, N.J., Sept. 22 /PRNewswire/ -- Who knew that simply putting on 21 - 30 pounds between your teens and your 50s could increase your risk of breast cancer after menopause? Now that word is getting out about the link...

Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and tr...

Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting

Monogram announces availability of HERmark and HER1 and HER3 Total Protein Assays in Collaborative Biomarker Study SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today announced that scientific collaborators have presente...

Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores

Study Published in the Journal of Clinical Oncology Proves Accurate Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) tod...

Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study

- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer Study Showing Objective Tumo...
Other Tags
(Date:7/10/2014)... Pa. , July 2, 2014  Unisys Corporation,s (NYSE: ... , Unisys Nederland N.V., today announced that it has ... deliver, implement and manage a new Basic Provision Biometrics solution ... Unisys won the contract with a solution based ... management software. The term of the contract is up to ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... 3, 2014 Research and Markets ( ... "Global Gesture Recognition & Touch-Less Sensing (2D, ... 2020" report to their offering ... Recognition & Touch-Less Sensing Market to Grow Exponentially. ... while, but the companies were unable to leverage ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
Other Contents